Close

We use cookies to improve your experience of our website. Privacy Policy

Skip to main content
Menu

Dr William Alazawi

William Alazawi

Reader & Consultant in Hepatology

Blizard Institute
School of Medicine & Dentistry, Queen Mary University of London

www.qmul.ac.uk/blizard/staff/centre-for-immunobiology/staff/william-alazawi.html

Publications of specific relevance to Predictive in vitro Models

Publications

2020

Heath H, Britton G, Kudo H, Renney G, Ward M, Hutchins R, Foster GR, Goldin R and Alazawi W (2020). Stat2 loss disrupts damage signalling and is protective in acute pancreatitis. J Pathol  10.1002/path.5481
Sattar N, Gill JMR and Alazawi W (2020). Improving prevention strategies for cardiometabolic disease. Nat Med  vol. 26, (3) 320-325. 10.1038/s41591-020-0786-7
Hou W, Janech MG, Sobolesky PM, Bland AM, Samsuddin S, Alazawi W and Syn W-K (2020). Proteomic screening of plasma identifies potential noninvasive biomarkers associated with significant/advanced fibrosis in patients with nonalcoholic fatty liver disease. Biosci Rep  vol. 40, (1) 10.1042/BSR20190395
Li W, Homer K, Hull S, Boomla K, Robson J and Alazawi W (2020). Obesity Predicts Liver Function Testing and Abnormal Liver Results. Wiley  Obesity  vol. 28, (1) 132-138. 10.1002/oby.22669

2019

Sattar N, Alazawi W and coauthors (2019). Authors' reply to McKenna-Barry and Ryan. Bmj  vol. 367, 10.1136/bmj.l6549
Alexander M, Loomis AK, van der Lei J, Duarte-Salles T, Prieto-Alhambra D, Ansell D, Pasqua A, Lapi F, Rijnbeek P, Mosseveld M, Avillach P, Egger P, Dhalwani NN, Kendrick S, Celis-Morales C, Waterworth DM, Alazawi W and Sattar N (2019). Non-alcoholic fatty liver disease and risk of incident acute myocardial infarction and stroke: findings from matched cohort study of 18 million European adults. Bmj  vol. 367, l5367-l5367. 10.1136/bmj.l5367
Michael E, Nadarajah L, Blunden M and Alazawi W (2019). Renal dysfunction in liver disease. Medicine (United Kingdom)  vol. 47, (10) 679-683. 10.1016/j.mpmed.2019.07.001
Alexander M, Loomis AK, van der Lei J, Duarte-Salles T, Prieto-Alhambra D, Ansell D, Pasqua A, Lapi F, Rijnbeek P, Mosseveld M, Waterworth DM, Kendrick S, Sattar N and Alazawi W (2019). Risks and clinical predictors of cirrhosis and hepatocellular carcinoma diagnoses in adults with diagnosed NAFLD: real-world study of 18 million patients in four European cohorts. Bmc Med  vol. 17, (1) 10.1186/s12916-019-1321-x
Nunez DJ, Alexander M, Yerges-Armstrong L, Singh G, Byttebier G, Fabbrini E, Waterworth D, Meininger G, Galwey N, Wallentin L, White HD, Vannieuwenhuyse B, Alazawi W, Kendrick S, Sattar N and Ferrannini E (2019). Factors influencing longitudinal changes of circulating liver enzyme concentrations in subjects randomized to placebo in four clinical trials. Am J Physiol Gastrointest Liver Physiol  vol. 316, (3) G372-G386. 10.1152/ajpgi.00051.2018
Waller K, James C, de Jong A, Blackmore L, Ma Y, Stagg A, Kelsell D, Odwyer M, Hutchins R and Alazawi W (2019). ADAM17-mediated reduction in CD14++ CD16+ monocytes ex vivo and reduction in intermediate monocytes with immune paresis in acute pancreatitis and acute alcoholic hepatitis. Frontiers in Immunology  vol. 10, (AUG) 10.3389/fimmu.2019.01902

2018

ALAZAWI W, Alexander M, Loomis AK, Fairburn-Beech J, van der Lei J, Duarte-Salles T, Prieto-Alhambra D, Ansell D, Pasqua A, Lapi F, Rijnbeek P, Mosseveld M, Avillach P, Egger P, Kendrick S, Waterworth D and Sattar N (2018). Real world data reveal a diagnostic gap in non-alcoholic fatty liver disease. Biomed Central  Real World Data Reveal a Diagnostic Gap in Non-Alcoholic Fatty Liver Disease  vol. 16, (130) 10.1186/s12916-018-1103-x
Alazawi W and Knolle PA (2018). Interfering with Kupffer cell replenishment: New insights into liver injury. J Hepatol  vol. 68, (4) 635-637. 10.1016/j.jhep.2018.01.011
De Silva S, Li W, Kemos P, Brindley JH, Mecci J, Samsuddin S, Chin-Aleong J, Feakins RM, Foster GR, Syn WK and Alazawi W (2018). Non-invasive markers of liver fibrosis in fatty liver disease are unreliable in people of south asian descent. Frontline Gastroenterology  vol. 9, (2) 115-121. 10.1136/flgastro-2017-100865

2017

Alazawi W, Bernabe E, Tai D, Janicki T, Kemos P, Samsuddin S, Syn W-K, Gillam D and Turner W (2017). Periodontitis is associated with significant hepatic fibrosis in patients with non-alcoholic fatty liver disease. Public Library of Science  Plos One  vol. 12, (12) e0185902-e0185902. 10.1371/journal.pone.0185902
Sheridan DA, Aithal G, Alazawi W, Allison M, Anstee Q, Cobbold J, Khan S, Fowell A, McPherson S, Newsome PN, Oben J, Tomlinson J and Tsochatzis E (2017). Care standards for non-alcoholic fatty liver disease in the United Kingdom 2016: A cross-sectional survey. Frontline Gastroenterology  vol. 8, (4) 252-259. 10.1136/flgastro-2017-100806
Shetty A, Cho W, Alazawi W and Syn W-K (2017). Methotrexate Hepatotoxicity and the Impact of Nonalcoholic Fatty Liver Disease. Am J Med Sci  vol. 354, (2) 172-181. 10.1016/j.amjms.2017.03.014

2016

Alazawi W, Pirmadjid N, Lahiri R and Bhattacharya S (2016). Inflammatory and immune responses to surgery and their clinical impact. Annals of Surgery  vol. 264, (1) 73-80. 10.1097/SLA.0000000000001691

2015

Tai FWD, Syn W-K and Alazawi W (2015). Practical approach to non-alcoholic fatty liver disease in patients with diabetes. Diabet Med  vol. 32, (9) 1121-1133. 10.1111/dme.12725
Lahiri R, Derwa Y, Bashir Z, Giles E, Torrance HD#32046#, Owen HC#32058#, O'Dwyer MJ#29886#, O'Brien A, Stagg AJ#19462#, Bhattacharya S, Foster GR#21549# and Alazawi W#25563# (2015). Systemic Inflammatory Response Syndrome After Major Abdominal Surgery Predicted by Early Upregulation of TLR4 and TLR5. Lippincott, Williams & Wilkins  Ann Surg  vol. 2015, (3) 10.5966/sctm.2012-0137

2014

Alazawi W, Mathur R, Abeysekera K, Hull S, Boomla K, Robson J and Foster GR (2014). Ethnicity and the diagnosis gap in liver disease: a population-based study. Br J Gen Pract  vol. 64, (628) e694-e702. 10.3399/bjgp14X682273
Ooi J, Chinthapalli S, O'Toole E#20462# and Alazawi W#25563# (2014). PWE-142 Is Liver Disease Overlooked In Patients With Psoriasis? Gut  vol. 63 Suppl 1, 10.1136/gutjnl-2014-307263.402
Tai F, Derwa Y, Naik S and Alazawi W (2014). PTH-080 Risk Profile For Non-alcoholic Fatty Liver Disease (nafld) In A Paediatric Specialist Care Setting. Gut  vol. 63 Suppl 1, A244-A245. 10.1136/gutjnl-2014-307263.526
Alazawi W, Mathur R, Abeysekera K, Hull S, Boomla K, Robson J and Foster G (2014). PTU-138 Population-based Study Of Ethnicity And The Diagnosis Gap In Liver Disease. Gut  vol. 63 Suppl 1, 10.1136/gutjnl-2014-307263.212
O'Brien AJ, Fullerton JN, Massey KA, Auld G, Sewell G, James S, Newson J, Karra E, Winstanley A, Alazawi W#25563#, Garcia-Martinez R, Cordoba J, Nicolaou A and Gilroy DW (2014). Immunosuppression in acutely decompensated cirrhosis is mediated by prostaglandin E2. Nat Med  vol. 20, (5) 518-523. 10.1038/nm.3516
Hull S, Mathur R, Boomla K, Chowdhury TA, Dreyer G, Alazawi W and Robson J (2014). Research into practice: Understanding ethnic differences in healthcare usage and outcomes in general practice. British Journal of General Practice  vol. 64, (629) 653-655. 10.3399/bjgp14X683053

2013

Alazawi W, Agarwal K, Suddle A, Aluvihare V and Heneghan MA (2013). Maintaining clinical governance when giving telephone advice. Frontline Gastroenterol  vol. 4, (4) 270-277. 10.1136/flgastro-2013-100351
Lahiri RP, Abeles A, Burnand KM, Alazawi W, Bhattacharya S, Foster GR and Knowles CH (2013). A cross sectional study of colonic diverticulosis in the London Bangladeshi population. United European Gastroenterol J  vol. 1, (3) 191-197. 10.1177/2050640613489282
Alazawi W#25563#, Heath H, Waters JA, Woodfin A#19770#, O'Brien AJ, Scarzello AJ, Ma B#29390#, Lopez-Otalora Y, Jacobs M, Petts G, Goldin RD, Nourshargh S#20399#, Gamero AM and Foster GR#21549# (2013). Stat2 loss leads to cytokine-independent, cell-mediated lethality in LPS-induced sepsis. Proc Natl Acad Sci U S A  vol. 110, (21) 8656-8661. 10.1073/pnas.1221652110

2012

George PM, Cunningham ME, Galloway-Phillipps N, Badiger R, Alazawi W, Foster GR and Mitchell JA (2012). Endothelin-1 as a mediator and potential biomarker for interferon induced pulmonary toxicity. Pulm Circ  vol. 2, (4) 501-504. 10.4103/2045-8932.105039
George PM, Badiger R, Alazawi W, Foster GR and Mitchell JA (2012). Pharmacology and therapeutic potential of interferons. Pharmacol Ther  vol. 135, (1) 44-53. 10.1016/j.pharmthera.2012.03.006
Alazawi W, Spyrou A, Lahiri R, Waters J and Foster GR (2012). FLAGELLIN-INDUCED IL-6 PRODUCTION IS SELECTIVELY IMPAIRED IN PATIENTS WITH CIRRHOSIS. Gut  vol. 61, A130-A130. 10.1136/gutjnl-2012-302514b.141
Patel C, Gill US, Alazawi W, Shaw P, Alstead E, Kallis Y, Kooner P, Marley R, Naik S, ChinAleong J, Goldin RD, Foster GR and Kennedy PTF (2012). EVALUATION OF LIVER FIBROSIS IN YOUNG ADULT PATIENTS WITH CHRONIC HEPATITIS B VIRUS. Gut  vol. 61, A133-A133. 10.1136/gutjnl-2012-302514b.148
Konishi H, Okamoto K, Ohmori Y, Yoshino H, Ohmori H, Ashihara M, Hirata Y, Ohta A, Sakamoto H, Hada N, Katsume A, Kohara M, Morikawa K, Tsukuda T, Shimma N, Foster GR, Alazawi W, Aoki Y, Arisawa M and Sudoh M (2012). An orally available, small-molecule interferon inhibits viral replication. Sci Rep  vol. 2, 10.1038/srep00259

2011

Alazawi W, Gamero A, Heath H, Smith P, Jacobs M, Waters J and Foster GR (2011). NF kappa B ACTIVATION BY TLR AGONISTS IS DEFICIENT IN MACROPHAGES LACKING STAT2. Gut  vol. 60, A43-A43. 10.1136/gutjnl-2011-300857a.93
Buczacki S, Shalhoub J, George PM, Vearncombe LM, Byrne PD and Alazawi W (2011). Benefits of knowledge-based interprofessional communication skills training in medical undergraduate education. Jrsm Short Rep  vol. 2, (8) 10.1258/shorts.2011.011065
Goodhand JR, Alazawi W and Rampton DS (2011). Systematic review: Clostridium difficile and inflammatory bowel disease. Aliment Pharmacol Ther  vol. 33, (4) 428-441. 10.1111/j.1365-2036.2010.04548.x
ALAZAWI W, Lewis H and Foster GR (2011). Other Liver Viruses. Elsevier  Medicine  vol. 39, (9) 561-563. 10.1016/j.mpmed.2011.06.005

2010

Alazawi W, Cunningham M, Dearden J and Foster GR (2010). Systematic review: outcome of compensated cirrhosis due to chronic hepatitis C infection. Aliment Pharmacol Ther  vol. 32, (3) 344-355. 10.1111/j.1365-2036.2010.04370.x
Alazawi W and Vearncombe LM (2010). Ready to Excel. Lulu 
ALAZAWI W and Foster GR (2010). Combination Therapy for Chronic Hepatitis B Virus Infection: Should we use it ab initio or Sequentially? Clinical Dilemmas in Viral Liver Disease , Editors: Foster G and Reddy KR. Wiley-Blackwell 

2009

ALAZAWI W (2009). Syncope in a Patient with Noonan Syndrome. Cases in Adult Congenital Heart Disease , Editors: Gatzoulis MA, Gary D Webb MD and Craig S Broberg MD. Churchill Livingstone 

2008

Alazawi W and Foster GR (2008). Advances in the diagnosis and treatment of hepatitis B. Curr Opin Infect Dis  vol. 21, (5) 508-515. 10.1097/QCO.0b013e32830fb924

2006

Herdman MT, Pett MR, Roberts I, Alazawi WOF, Teschendorff AE, Zhang X-Y, Stanley MA and Coleman N (2006). Interferon-beta treatment of cervical keratinocytes naturally infected with human papillomavirus 16 episomes promotes rapid reduction in episome numbers and emergence of latent integrants. Carcinogenesis  vol. 27, (11) 2341-2353. 10.1093/carcin/bgl172

2004

Alazawi W, Pett M, Strauss S, Moseley R, Gray J, Stanley M and Coleman N (2004). Genomic imbalances in 70 snap-frozen cervical squamous intraepithelial lesions: associations with lesion grade, state of the HPV16 E2 gene and clinical outcome. Br J Cancer  vol. 91, (12) 2063-2070. 10.1038/sj.bjc.6602237
Morgan C, Alazawi W, Sirieix P, Freeman T, Coleman N and Fitzgerald R (2004). In vitro acid exposure has a differential effect on apoptotic and proliferative pathways in a Barrett's adenocarcinoma cell line. Am J Gastroenterol  vol. 99, (2) 218-224. 10.1111/j.1572-0241.2004.04054.x
Pett MR, ALAZAWI W, Roberts I, Dowen S, Smith DI, Stanley MA and Coleman N (2004). Acquisition of High-Level Chromosomal Instability Is Associated with Integration of Human Papillomavirus Type 16 in Cervical Keratinocytes. American Association For Cancer Research  Cancer Research  vol. 64, (4) 1359-1368. 10.1158/0008-5472.CAN-03-3214

2003

Alazawi W, Gonzalez M, Abraham J, Arends M, Coleman N and Wilson C (2003). Primary or secondary malignancy? Fingerprint evidence. Clin Oncol (R Coll Radiol)  vol. 15, (7) 408-411. 10.1016/s0936-6555(03)00062-1
ALAZAWI W, Morris LS, Stanley MA, Garrod DR and Coleman N (2003). Altered expression of desmosomal components in high-grade squamous intraepithelial lesions of the cervix. Springer  Virchows Archiv: The European Journal of Pathology  vol. 443, (1) 51-56. 10.1007/s00428-003-0771-9

2002

Alazawi W, Pett M, Arch B, Scott L, Freeman T, Stanley MA and Coleman N (2002). Changes in cervical keratinocyte gene expression associated with integration of human papillomavirus 16. Cancer Res  vol. 62, (23) 6959-6965.
Alazawi W, Pett M, Freeman T, Stanley M and Coleman N (2002). Changes in host cell genome and transcriptome associated with integration of HPV 16 in cervical keratinocytes. J Pathol  vol. 198, 8A-8A.